MYNN (myoneurin) is a transcription factor located on chromosome 3.2 that functions as a DNA-binding protein with RNA polymerase II-specific transcriptional activity 1. The protein localizes to the nucleoplasm and nucleus where it regulates transcription by RNA polymerase II at cis-regulatory regions [GO Annotations]. Computationally, the rs10936599 coding variant was predicted functionally deleterious and shows significant structural deviation from wild-type protein with altered binding properties 1. MYNN variants associate with multiple disease processes. The rs10936599 polymorphism shows strong association with bladder cancer risk in Turkish populations, with CT and CT+TT genotypes conferring decreased risk while CC genotype increases risk twofold 2. Additionally, smoking interacts with MYNN genetic variants to influence urothelial cancer risk, particularly with gene-smoking interactions of lesser magnitude than NAT2 3. MYNN also associates with colorectal cancer survival, where rs10936599 contributes to polygenic risk scores predicting worse disease-free and overall survival 4. Recent GWAS identified MYNN/LRRC34 as a locus involved in female genital tract polyp development through DNA repair, cell proliferation, and cell growth mechanisms 5. Furthermore, MYNN variants associate with telomere length regulation independent of linkage disequilibrium mechanisms 6. Finally, MYNN methylation status serves as an optimal diagnostic biomarker for Alzheimer's disease 7.